http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20180115297-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b01dcd61775e996fac631d4b10c4e87f http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5073a0063d6be9e25c14d2af0a1ee89 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 2017-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee9e4bf00eeae6e83df20c96ba90c25d |
| publicationDate | 2018-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20180115297-A |
| titleOfInvention | The use of BYL719 (alpericib) for the treatment of PIK3CA-related overgrowth spectra (PROS-CLOVES syndrome) |
| abstract | The present invention relates to a method for the treatment of PIK3CA-related and growth spectrum (PROS), more particularly congenital, lipoma, overgrowth, vascular malformation, epidermal nevus and spinal / skeletal abnormalities and / or scoliosis 10 syndrome will be. Until now, there has been no specific treatment for patients and there was no animal model of PROS to better understand the physiopathology of the disorder. We have developed a genetic mouse model of PROS that reproduces human disease and demonstrated the efficacy of BYL719. Based on these results, we treated BYL719 with two patients, one adult and one child with severe COLVES syndrome. The drug had a potent effect on the disease at 15 and induced rapid recovery of all affected organs in 2 patients. Accordingly, the present invention relates to a method of treating PROS in a subject, comprising administering a therapeutically effective amount of BYL719 to a patient in need thereof. |
| priorityDate | 2016-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 65.